• Archives of Pharmacal Research
• /
• v.13 no.1
• /
• pp.97-100
• /
• 1990

A convenient route is reported for the synthesis of fused pyrrolo [2, 3-d][1, 3]-oxazine and pyrrolo [2, 3-d]-pyrimidine derivatives from 2-amino-1-benzyl-3-t-butoxy-carbonyl-4, 5-dimethylpyrrole.

• Journal of the Korean Chemical Society
• /
• v.66 no.6
• /
• pp.442-450
• /
• 2022

Diverse pyrrolo[3,2-d]pyrimidines that are expected to exhibit bioactivity were synthesized through O-arylation and Suzuki coupling reactions. Microwave-assisted O-arylation was successfully performed using a Cu metal catalyst, so that 4 position of pyrrolo[3,2-d]pyrimidine could be substituted with phenol group. In addition, 4-aryl substituted pyrrolo[3,2-d]pyrimidines were synthesized with good to excellent yields by microwave-assisted Suzuki coupling reaction using a Pd metal catalyst. By using microwaves as reaction conditions for diversification of derivatives, it was possible to dramatically overcome the disadvantages of traditional heat reactions of long reaction times and heat transfer efficiency problems. The result of this study can be used to be diversify pyrrolo[3,2-d]pyrimidine derivatives, which are expected to play an important role in the drug discovery research.

• Bulletin of the Korean Chemical Society
• /
• v.29 no.11
• /
• pp.2231-2236
• /
• 2008

• Bulletin of the Korean Chemical Society
• /
• v.35 no.2
• /
• pp.617-621
• /
• 2014

An efficient and selective method for the synthesis of ethyl 2-amino/aryloxy-3-aryl-4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carboxylate derivatives has been developed. The main process involved the reaction of diethyl 1-phenyl-3-((triphenylphosphoranylidene)amino)-1H-pyrrole-2,4-dicarboxylate and aromatic isocyanates, followed by addition of amines/phenols in the presence of catalytic amount of sodium ethoxide or solid potassium carbonate.

• Bulletin of the Korean Chemical Society
• /
• v.26 no.5
• /
• pp.719-728
• /
• 2005

A novel 2-amino-4-(8-quinolinol-5-yl)-1- (p-tolyl)-pyrrole-3-cabonitrile (2) was obtained by the reaction of 2-[2-bromo-1-(8-hydroxyquinolin-5-yl)-ethylidene]-malononitrile (1) with p-toluidene. The new synthon compound (2) could be annelated to the corresponding pyrrolo[2,3-d]pyrimidines (4, 6, 7, 26-28), triazolo[1,5-c]pyrrolo[3,2-e]pyrimidines (10, 29, 30), pyrrolo[2,3-c]pyrazoles (11-15), pyrrolo[1,2-a]pyrrolo[3,2-e] pyrimidine (17) and imidazo[1,2-c]pyrrolo[3,2-e]pyrimidines (18-25) via the reaction with some reagents such as acetic anhydride, formamide, triethyl orthoformate, hydrazine hydrate, hydroxylamine, ethylenediamine, carbon disulfide and phosphorus oxychloride. Chemical and spectroscopic evidences for the structures of these compounds are presented. The antifungal and antibacterial activity of the newly synthesized comounds were evaluated.

• Bulletin of the Korean Chemical Society
• /
• v.35 no.12
• /
• pp.3502-3508
• /
• 2014

The first synthetic route to 5'-norcarbocyclic C-nucleoside [7-oxa-7,9-dideazadenosine (furo[3,2-d]pyrimidine) and 9-deazaadenosine (pyrrolo[3,2-d]pyrimidine)] phosphonic acids from commercially available 1,3-dihydroxy cyclopentane was described. The key C-C bond formation from sugar to base precursor was performed using Knoevenagel-type condensation from a ketone derivative. Synthesized C-nucleoside phosphonic acids were tested for anti-HIV activity as well as anti-leukemic activity. Compound 26 showed significant anti-leukemic activity.

• Journal of Microbiology and Biotechnology
• /
• v.20 no.2
• /
• pp.433-437
• /
• 2010

In the course of screening for novel modulators of cell cycle progression and apoptosis as anticancer drug candidates, we generated an analog of sangivamycin, MCS-C2, which was elucidated as 4-amino-6-bromo-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide. In the present study, we evaluated the molecular mechanisms of MCSC2-induced cell cycle arrest and apoptosis in A549 human lung cancer cells. To investigate the effects of MCS-C2 on cell cycle progression in A549 cells, we measured the DNA content of A549 cells treated with $5\;{\mu}M$ MCS-C2 using flow cytometry. The analysis revealed an appreciable $G_2$ phase arrest in treated cells. This event was associated with significant upregulation of p53 and $p21^{Cip1}$. In addition, the TUNEL assay was used to examine apoptotic induction in treated cells, and the effects of MCS-C2 on the expression of apoptosis-associated proteins were examined by Western blot. Apoptotic induction in MCS-C2-treated A549 cells was associated with cytochrome c release from mitochondria, which in turn resulted in the activation of caspase-9 and -3 and the cleavage of poly(ADP-ribose) polymerase (PARP). Based on these results, we conclude that MCS-C2 is a candidate therapeutic agent for the treatment of human lung cancer via upregulation and activation of p53.